申请人:Solvay Pharmaceuticals GmbH
公开号:US20040162345A1
公开(公告)日:2004-08-19
Compounds having combined, particularly concurrent, inhibitory activity on neutral endopeptidase (NEP) and on a novel metalloprotease designated IGS5, or of a pharmaceutically acceptable salt or solvate or biolabile ester thereof, and related methods for treating and for the manufacture of a pharmaceutical composition for a mammal, preferably a larger mammal such as a human, suffering from or being susceptible to a disease or condition which can be alleviated or inhibited by combined or concurrent inhibition of NEP and IGS5. Treatments for diseases or conditions where big-ET-1 levels are elevated, or where ET-1 is upregulated, where such diseases or conditions can be alleviated or inhibited by combined or concurrent inhibition of NEP and IGS5.
对中性内肽酶(NEP)和一种被命名为IGS5的新型金属蛋白酶或其药学上可接受的盐或溶解物或生物可降解酯具有联合、特别是并发抑制活性的化合物,以及用于治疗和制造药物组合物的相关方法,该药物组合物用于哺乳动物,最好是较大的哺乳动物,如人类,患有或易患可通过联合或并发抑制NEP和IGS5而减轻或抑制的疾病或病症。治疗big-ET-1水平升高或ET-1上调的疾病或病症,这些疾病或病症可通过联合或同时抑制NEP和IGS5而减轻或抑制。